Tris Pharma

Trial and FDA signals

• FDA complete response letter Received an FDA complete response letter (NDA 220138, letter dated Jun 15, 2026). FDA NDA 220138 (Jun 15, 2026)
  Evidence (1 event)

  • Jun 15, 2026 · FDA NDA 220138
    CRL text (OCR, redacted by FDA; first 200 chars from "COMPLETE RESPONSE"): COMPLETE RESPONSE Tris Pharma, Inc. Attention: Rashmi Aravind Senior Director of Regulatory Affairs Monmouth Junction, NJ (street omitted) Dear Rashmi Aravind: Please refer to your new dr

Job counts as of Oct 18, 2026. All trial and FDA signals